MSGERC Call for Cases of Challenging Invasive Fungal Infections

Do you have an interesting case of an IFI in a patient with COVID-19? Or a challenging case of candidiasis or endemic mycoses? Please consider sending your case to us.  We are compiling a range of cases for discussion that illustrate diagnostic and management challenges for these difficult infections. Select cases will be workshopped by our expert faculty.

Please click here to download and fill out the case template form. Once the form is completed, please email your case to  jones.5342@osu.edu.

Thank you in advance!

This educational initiative was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (CDC-RFA-CK20-2003) to the University of Alabama at Birmingham. The University of Alabama at Birmingham is collaborating with the Mycoses Study Group Education & Research Consortium and Terranova Medica, LLC, on this initiative. The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this resource center do not necessarily represent the policy of CDC or HHS and should not be considered an endorsement by the Federal Government.

CALL FOR CASES

COVID-19—ASSOCIATED FUNGAL INFECTION

These cases, provided by healthcare providers across the United States, illustrate challenges encountered in recognizing and managing COVID-19—associated pulmonary aspergillosis (CAPA) and other COVID-19—associated invasive fungal infections (CA-IFIs). Where available, we’ve included link-aways to specific discussion of these cases in continuing education activities and social media posts.

Please review the case links below

• Case 1: CAPA development in an Anakinra-treated patient
• Case 2: CAPA treated with voriconazole – See continuing education activity  http://www.funguscme.org/Covid19Cases/index.html for case discussion.
• Case 3: CAPA patient with extensive imaging
• Case 4: COVID-19 patient with clinical decompensation despite appropriate antibiotic therapy – See continuing education activity http://www.funguscme.org/Multidisciplinary/index.html for case discussion.
• Case 5: CAPA case illustrating the lack of traditional IPA risk factors
• Case 6: COVID-19 patient treated with immunosuppression who develops CAPA and pulmonary cryptococcosis – See continuing education activity http://www.funguscme.org/Multidisciplinary/index.html for case discussion.
• Case 7: COVID-19 patient who experiences a coccidioidomycosis relapse – See continuing education activity  http://www.funguscme.org/Covid19Cases/index.html for case discussion.
• Case 8: Autopsy-proven CAPA – See continuing education activity  http://www.funguscme.org/Covid19Cases/index.html for case discussion.